Highest-materiality recent filing
Director Anne O'Riordan not standing for re-election at Jazz's 2026 annual meeting
Class III director Anne O'Riordan will not seek re-election at the 2026 annual meeting, continuing board refreshment.
Jazz Pharma Q1 revenue $1.1B (+19% YoY), EPS $4.43 GAAP / $6.34 adj; Zanidatamab PDUFA Aug 25
Total revenues $1.1B (+19% YoY); GAAP EPS $4.43, non-GAAP adj. EPS $6.34; operating cash flow $408M.
Jazz Pharma FY2025 revenue $4.3B (+5% YoY); GAAP net loss $356M vs $560M income in 2024
Total revenues record $4.3B in FY2025 (+5% YoY); Q4 revenue $1.2B (+10% YoY).
Jazz Pharma reaffirms FY2025 total revenue guidance at JPM conference
Expects to meet previously announced total revenue guidance range for FY2025 year ended Dec 31, 2025.
Positive Phase 3 results for Ziihera: significant PFS/OS improvement in first-line HER2+ GEA
Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS clinically meaningful trend at first interim analysis.
Jazz Pharma Q3 rev $1.13B (+7%), GAAP EPS $4.08, adj. EPS $8.13; FY25 rev guid narrowed
Total revenues $1.126B (+7% YoY); GAAP net income $251M, non-GAAP adj. net income $501M.
Jazz Pharma appoints Dr. Ted Love to board; director Kenneth O'Keefe to retire Dec 1, 2025
Dr. Ted Love appointed as Class I director effective Dec 1, 2025, term expiring at 2027 AGM.
Jazz settles patent litigation with Avadel; grants Lumryz license, pays $90M
Jazz pays $90M lump sum to Avadel and waives certain prior royalties to settle all litigation.
Jazz Q2 GAAP net loss $718M; revenue $1.05B up 2%; updates FY25 guidance
Q2 total revenues $1.05B, up 2% YoY; GAAP net loss $718.5M vs $168.6M profit in Q2 2024.
Jazz Pharma shareholders elect four directors and ratify KPMG as auditor at 2025 AGM
All four director nominees were elected: Cook, Enright, Mulligan, Riedel, each with >46M votes for.
Jazz Pharma appoints Renee Gala as President & CEO, effective Aug 11, 2025; Cozadd remains Chair
Renee Gala, previously President & COO, becomes President & CEO effective August 11, 2025, and joins the Board.
Jazz Q1 revenues flat at $898M; GAAP net loss widens to $92.5M; updated guidance after Chimerix
GAAP net loss $92.5M ($1.52 loss/share) vs $14.6M loss in 1Q24; adjusted net income $105.2M ($1.68 EPS) vs $178.4M ($2.63).
Jazz completes $935M acquisition of Chimerix, adds dordaviprone to pipeline
Acquisition completed for ~$935M cash; $8.55 per share.
Jazz Pharma to pay $145M to settle Xyrem antitrust class action; records Q1 charge
Jazz Pharmaceuticals Ireland subsidiary agrees to pay $145M lump sum to settle indirect Xyrem purchaser class action.
Jazz Pharmaceuticals to acquire Chimerix for $8.55/share in all-cash tender offer
Tender offer to commence by March 24, 2025; Chimerix board unanimously recommends.
Jazz Pharma to acquire Chimerix for ~$935M ($8.55/sh), adding brain-tumor drug dordaviprone
All-cash tender offer at $8.55/sh; represents ~72% premium over Chimerix's March 4 close.
Jazz Pharma reports record 2024 revenue $4.1B; guides 2025 rev $4.15-4.40B
Record total revenue $4.07B for FY2024, up 6% YoY; Q4 revenue $1.09B, up 8% YoY.
Jazz Pharma confirms FY2024 revenue guidance met at J.P. Morgan conference
Company expects to meet previously announced total, neuroscience and oncology revenue guidance for year ended Dec 31, 2024.
Jazz CEO Bruce Cozadd to retire by end of 2025; company to search for successor
Bruce Cozadd notified Board of intent to retire as CEO upon appointment of successor.
Jazz Pharmaceuticals expands revolver to $885M, extends maturity to 2029
Revolving credit facility increased from $500M to $885M; maturity extended from May 2026 to Nov 2029.
Jazz Pharmaceuticals receives FDA accelerated approval for Ziihera in HER2+ biliary tract cancer
FDA approved Ziihera (zanidatamab-hrii) for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC.
Jazz Q3 revenue tops $1.05B, raises EPS guidance, affirms 2024 revenue outlook at $4.0-4.1B
Q3 2024 record revenue >$1.05B; key growth drivers (Xywav, Epidiolex, Rylaze) up 14% YoY.
Jazz Pharma ends Palo Alto lease early, signs new lease nearby
Existing lease at 3170 Porter Drive terminated effective June 30, 2025 (original expiry Oct 2029).
Jazz Prices $1B 3.125% Exchangeable Notes Due 2030, Preps $500M Loan Repayment & $150M Buyback
$1.0B aggregate principal of 3.125% exchangeable senior notes due 2030, including $150M overallotment exercised.
Jazz Pharma wins partial injunction against Avadel's Lumryz, ongoing royalty above 3.5%
On August 27, 2024, U.S. District Court granted Jazz's motion for permanent injunction against Avadel.
Jazz Q2 revenue >$1B record; key drugs up 13-22%; guides EPS higher
Xywav sales +13%, Epidiolex +22%, Rylaze +6% YoY; oncology revenue +10% YoY.
Jazz Pharma shareholders elect directors, ratify auditor, approve say-on-pay at 2024 AGM
All four director nominees elected (Hamill, Kennedy, O'Keefe, Smith) with 50.5M-52.8M votes for.
Jazz reprices $2.7B term loan; margin cut 75 bps to 2.25%+SOFR
Entered Amendment No. 2 to Credit Agreement; Tranche B-2 Dollar Term Loans replace Tranche B-1 at same $2,707,000,000 outstanding.
Director Catherine Sohn to retire, not standing for re-election at 2024 AGM
Catherine Sohn, Pharm.D. notified board of retirement effective at 2024 annual general meeting.
Jazz Pharma Q1 GAAP net loss $14.6M, non-GAAP EPS $2.68; affirms FY24 revenue guidance $4.0-4.2B
Total revenues $902M (+1% YoY); GAAP net loss $14.6M ($0.23 loss/diluted) vs net income $69.4M ($1.04/diluted) in 1Q23.
Jazz Pharma FY23 net income $414.8M vs loss; guides FY24 rev $4.0-4.2B
Total revenue $3.84B in 2023, up 5% YoY; Q4 revenue $1.01B, up 4% YoY.
Jazz Pharmaceuticals appoints Patrick Kennedy to Board; Peter Gray not standing for re-election
Patrick Kennedy appointed as Class I director effective March 1, 2024; term expires at 2024 AGM.
Jazz Pharmaceuticals names Philip Johnson as CFO, effective March 1, 2024
Philip Johnson appointed EVP and CFO; succeeds Renée Galá who became President and COO in October 2023.
Jazz reprices $2.72B term loans; margin cut 50 bps to Term SOFR+3.00%
Existing $2.7225B Initial Dollar Term Loans refinanced into same principal of Tranche B-1 Dollar Term Loans.
Jazz Pharma reaffirms 2023 revenue guidance; sees 2024 double-digit growth for key drugs
Reaffirms 2023 total, neuroscience, and oncology revenue guidance range.
Jazz Pharmaceuticals EVP & GM US Kim Sablich to depart Dec 31, 2023
Kim Sablich, EVP and General Manager, US, will depart the company effective December 31, 2023.
Jazz Pharmaceuticals Reports Q3 2023 Revenue of $972M, Raises Full-Year Guidance
Xywav net product sales grew 30% year-over-year to $331.6M; total oxybate revenue annualizing at $1.9B
Jazz Pharma President & COO Swisher to retire; CFO Galá promoted to COO; interim CFO named
Daniel Swisher Jr., President & COO, to retire effective Mar 31, 2024; duties cease Oct 1, 2023.
Jazz Pharma Q2 revenue $957M (+3% YoY); GAAP EPS $1.52 beats; raises FY guidance
Q2 total revenue $957M (+3% YoY); GAAP net income $104.4M ($1.52 diluted EPS) vs $34.7M ($0.55) prior year.
Jazz Pharmaceuticals files lawsuit challenging FDA approval of Lumryz
Filed complaint in U.S. District Court for DC seeking to vacate FDA's May 1, 2023 approval of Lumryz NDA.
Jazz Q1 EPS $1.04, adj. $3.95; rev $893M (+10%); Xywav +49%, guidance affirmed
GAAP net income $69.4M ($1.04 EPS) vs $1.6M ($0.03) in 1Q22; non-GAAP adj. net income $285.3M ($3.95 EPS) vs $261.9M ($3.73).
Jazz Pharma reports record 2022 revenue of $3.7B, up 18% YoY; guides 2023 revenue $3.675-3.875B
Record 2022 total revenue $3.7B (+18% YoY); 2023 revenue guidance $3.675-3.875B (3% growth at midpoint).
Jazz Pharma reaffirms FY2022 revenue guidance at J.P. Morgan conference
Company expects to meet previously announced total, neuroscience and oncology revenue guidance for FY2022.
Jazz Pharmaceuticals sues 10 generic filers over Epidiolex patents; seeks 30-month stay
10 ANDA filers, including Teva, Padagis, Apotex, Lupin, Taro, and others, filed paragraph IV certifications for generic Epidiolex.
Jazz exercises zanidatamab option; pays $325M; 41.3% ORR in BTC trial
Jazz exercised option to retain exclusive rights to zanidatamab in U.S., Europe, and Japan.
Jazz acquires exclusive zanidatamab rights from Zymeworks for $50M upfront
Upfront $50M non-refundable cash payment; potential $325M payment after HERIZON-BTC-01 top-line data.
Jazz completes ex-U.S. divestiture of Sunosi to Axsome
Completed ex-U.S. divestiture of Sunosi (solriamfetol) to Axsome Therapeutics on November 14, 2022.
Jazz Pharma Q3 revenue $940.7M (+12% YoY); raises FY guidance mid-point to $3.65B
Q3 total revenue $940.7M, up 12% YoY; driven by Xywav, Epidiolex, and Rylaze demand.
Jazz licenses zanidatamab from Zymeworks for up to $1.76B; $50M upfront, $325M option payment
Exclusive rights in U.S., Europe, Japan for HER2-targeted bispecific antibody zanidatamab.
Jazz Pharma Q2 revenue $932.9M (+24% YoY), affirms FY2022 guidance, net leverage target met early
Q2 2022 total revenues $932.9M, up 24% YoY; strong commercial execution across franchises.
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
On May 31, 2024, Catherine Sohn, Pharm.D. notified the board of directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”), that she is retiring and will not stand for re-election to the Board, when her term expires, at the Company’s 2024 annual general meeting of shareholders.
Peter Gray notified the Board that he will not stand for re-election to the Board, when his term expires, at the 2024 Annual Meeting.
appointed Patrick Kennedy to the Board, effective as of March 1, 2024, as a Class I director
On February 21, 2024, Jazz Pharmaceuticals plc (the “Company”) announced the appointment of Philip Johnson as the Company’s Executive Vice President and Chief Financial Officer, effective as of March 1, 2024.
On December 15, 2023, Jazz Pharmaceuticals plc (the “Company”) announced that Kim Sablich, Executive Vice President and General Manager, US, will be departing the Company, and that effective as of December 31, 2023, Ms. Sablich will no longer serve in that role or as an executive officer of the Company.
Effective as of October 1, 2023, Patricia Carr, the Company’s Senior Vice President and Chief Accounting Officer, will serve as the Company’s principal financial officer on an interim basis while the Company conducts a search for Ms. Galá’s replacement as the Company’s Executive Vice President and Chief Financial Officer.
Mr. Swisher will cease performing the duties and responsibilities of the Company’s President and Chief Operating Officer and will resign from any office or directorship at any affiliated entity of the Company, effective October 1, 2023.
On September 11, 2023, the Board appointed Renée Galá as the Company’s President and Chief Operating Officer, effective as of October 1, 2023, to succeed Mr. Swisher as the Company’s President and Chief Operating Officer.
Max materiality 0.90 · Median 0.75 · Most common event earnings